THERAMetrics has been granted a patent for a pharmaceutical kit that includes targeted treatment of idiopathic pulmonary fibrosis.

The issued patent protects a personalized medicine technique to address IPF through inhalation of an Interferon gamma based therapy, which is an already approved treatment for other diseases through subcutaneous injection, such as Multiple Sclerosis.

The research project that led to the development of this newly-patented technology used THERAMetrics’ DRR2.0, which is a versatile intelligence system for Drug Repurposing and Repositioning, Target Identification, Lead Optimization, Safety Evaluation, or Medical writing of Patent applications, and Orphan Drug applications.

THERAMetrics has also been granted Orphan Drug Designations to use Interferon gamma in IPF, which was awarded by the European Union and by the United States Food and Drug Administration.

View the full story at